Intracervical release of ST-1435 for contraception.
Seven women used an ST-1435-releasing intracervical contraceptive device (ST-ICD), inserted immediately after the cessation of menstrual bleeding. Patterns of bleeding and clinical performance were evaluated and plasma concentrations of ST-1435, estradiol, progesterone and gonadotropins were measured by radioimmunoassays. The results of ten months of treatment are presented. There were no uniform patterns of bleeding. No hormonal side-effects were registered. The plasma concentration of ST-1435 reached 100 pg/ml within two hours after insertion of an ST-ICD. No ovulations occurred during the initial three months of treatment. A rapid decline in the plasma concentrations of ST-1435 was observed; during the tenth month the concentration of ST-1435 was under the sensitivity of the radioimmunoassay of ST-1435. Hence, the release of ST-1435 from Silastic was too rapid for long-acting contraceptive purposes.
D000328:Adult; D002584:Cervix Uteri; D003271:Contraceptive Agents, Female / Q000008:administration & dosage*; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood; D008657:Metabolic Clearance Rate; D009652:Norpregnenes / Q000008:administration & dosage*; D009653:Norprogesterones / Q000008:administration & dosage* / Q000097:blood; D010060:Ovulation / Q000187:drug effects; D011374:Progesterone / Q000097:blood
D003271:Contraceptive Agents, Female; D009652:Norpregnenes; D009653:Norprogesterones; D011374:Progesterone; D004958:Estradiol; C029167:ST 1435; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone